The osteogenic effect of newly developed bisphosphonate (Disodium Dihydrogen-4-[(methylthio) phenylthio] Methane- Bisphosphonate (MPMBP)) was examined for clinical application in bone damage. A bone defect was made in the femur of ninety-seven male Wistar rats. 30µl of MPMBP (experimental group) or saline (control group) was injected around defect once every 3 days. The osteogenic effect to 4 weeks was performed at 1, 2, 3 and 4 weeks (experiment 1). Long-term observation was performed at 12 and 24 weeks after discontinuation of administration of MPMBP at 3 weeks (experiment 2). Newly formed bone was examined radiographically and histologically in both experiments. The elemental analysis was performed to investigate the quality of bone by energy-dispersive X-ray analysis. In experiment 1, newly bone formation is observed in the bone marrow cavity and cortical defect in both groups. The bone volume at 4 weeks was decreased in control group and maintained in experimental groups. In experiment 2, newly formed bone in bone marrow cavity was absorbed at 12 weeks in control group, and showed gradually decrease to 24 weeks in experimental group. The Ca/P of newly formed bone showed little difference between control and experimental groups. It was confirmed that the MPMBP administration had local effects, showing the promotion of new bone formation and long-term bone remodeling.
- Bone formation
- Bone remodeling
- Disodium dihydrogen-4-[(methylthio) phenylthio] methane- bisphosphonate (MPMBP)
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Orthopedics and Sports Medicine
- Cell Biology